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Abstract: Most human proteins are glycosylated. Attachment of complex oligosaccharides to the
polypeptide part of these proteins is an integral part of their structure and function and plays a central
role in many complex disorders. One approach towards deciphering this human glycan code is to
study natural variation in experimentally well characterized samples and cohorts. High-throughput
capable large-scale methods that allow for the comprehensive determination of blood circulating
proteins and their glycans have been recently developed, but so far, no study has investigated the
link between both traits. Here we map for the first time the blood plasma proteome to its matching
N-glycome by correlating the levels of 1116 blood circulating proteins with 113 N-glycan traits,
determined in 344 samples from individuals of Arab, South-Asian, and Filipino descent, and then
replicate our findings in 46 subjects of European ancestry. We report protein-specific N-glycosylation
patterns, including a correlation of core fucosylated structures with immunoglobulin G (IgG) levels,
and of trisialylated, trigalactosylated, and triantennary structures with heparin cofactor 2 (SERPIND2).
Our study reveals a detailed picture of protein N-glycosylation and suggests new avenues for the
investigation of its role and function in the associated complex disorders.
Keywords: glycomics; proteomics; N-glycosylation; population study; aptamers; HILIC-UPLC;
SOMAscan
1. Introduction
Protein glycosylation is a ubiquitous form of protein modification and plays a central role in many
biological processes [1]. Glycans have been proposed to be directly involved in the pathophysiology
of many major diseases [2]. Although carbohydrates are one of the major biological building
blocks, understanding of the human glycan code lags far behind that of DNA, RNA, and proteins.
High-throughput characterization of blood samples from large population studies using deep molecular
phenotyping technologies can provide an unbiased view of the participant’s health state and associated
variations in their molecular blood composition may thereby reveal novel molecular biomarkers for
diagnosis and disease progression. The resulting multi-omics data sets allow for the identification of
functional relationships between molecular traits and their mapping onto potentially health-relevant
pathways [3], as exemplified by recent studies on the human blood metabolome–transcriptome
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interface [4], the link between the blood methylome and metabolome [5], and genome-wide association
studies with the blood proteome [6] and metabolome [7]. Here we extend this approach to investigate
the relationship between natural variation observed in the blood circulating proteome and its associated
N-glycome. Both types of deep molecular phenotypes (“-omics”) have only recently become accessible
to high-throughput measurement. To the best of our knowledge this is the first study of the relationship
between the blood proteome and its N-glycome and may shed new light on the specific glycan garments
of blood circulating proteins.
Due to their high concentration range, blood circulating proteins are intrinsically difficult to
assess by mass-spectrometry. We therefore deployed a highly multiplexed, sensitive, quantitative, and
reproducible proteomics tool (SOMAscan™, Boulder, CO, USA) [8]. The SOMAscan assay is based
on a new generation of protein-capture aptamers (slow off-rate modified aptamer, SOMAmer™, City,
Country). These SOMAmers include naturally occurring and chemically modified nucleotides and
are selected from large randomized nucleic acid libraries to bind specifically to proteins implicated in
numerous diseases and physiological processes and to target a broad range of secreted, intracellular,
and extracellular proteins. The assay used in this study determines the levels of 1129 native proteins
in complex matrices by transforming each individual protein concentration into a corresponding
SOMAmer concentration, which is then quantified by microarray. It offers a high dynamic range
and allows quantifying proteins over eight orders of magnitude in abundance (from femtomolar to
micromolar), with low limits of detection (38 fM median LOD) and excellent reproducibility (5.1%
median % CV). To date, the SOMAscan assay has been applied successfully to biomarker discovery
and validation in many pharmaceutical research and development projects, diagnostics discovery
and development projects, and academic research projects, including Alzheimer’s disease [9,10],
Duchenne muscular dystrophy [11], aging [12], cancer [13,14], cardiovascular disease [15], genome-wide
association studies [6], and in combination with mRNA sequencing [16].
N-glycosylation is a co- and post-translational protein modification process that influences the
structure, cellular localization, and function of the majority of human proteins [17,18]. It consists in
the covalent linkage of complex oligosaccharides to specific protein sites, and many proteins only
become functional after glycosylation. Variation in the glycome make-up associates with disease
development [1] and response to medication [19]. Moreover, glycans have been shown to constitute
markers of chronological and biological age [20], Parkinson’s disease [21], and kidney function [22].
While the protein sequence is unambiguously coded by the respective gene, the glycan configuration is
flexible and influenced by the environment [23]. Analysis of the glycoconjugates is challenging due
to the complex branched structures of the sugars and their comparative fragility. Thanks to recent
advances in high-throughput technologies the systematic analysis of the glycome composition in
large population cohorts and clinical studies is now feasible [24]. For the study of total plasma or
serum N-glycomes, glycans are released from total plasma proteins using denaturation and enzymatic
cleavage, followed by labelling with 2-aminobenzamide and profiling using hydrophilic interaction
ultra-performance liquid chromatography (HILIC-UPLC).
In this study we analysed the correlations between proteomics and N-glycomics measurements
made in blood samples of participants of the QMDiab and the TwinsUK cohort (see methods) under
the assumption that a correlation between a specific protein and N-glycan is indicative of one of the
following: a direct physical link between both, e.g., cases where the protein is a major source of the
observed N-glycan, the protein controls the production of the N-glycan, e.g., an enzyme that acts in the
biosynthesis of a specific N-glycan, the N-glycan controls the abundance of the protein in the blood,
e.g., through regulation of translocation processes, or both protein and N-glycan levels are controlled
by a confounding factor, like disease state, smoking, or age. As this is the first study of its kind, we
focus on protein–glycan associations that are replicable and robustly observed in different ethnicities.
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2. Results
2.1. Correlation between Plasma N-Glycans and Blood Circulating Protein Levels
Using the SOMAscanTM platform we quantified the levels of 1129 proteins in blood EDTA plasma
samples of 352 participants of the Qatar Metabolomics Study on Diabetes (QMDiab) [25] and in parallel
determined the total plasma N-glycome for 344 of these samples (a smaller sample numbers of N-glycan
measurements was due to limited sample availability). For replication, we included data from 46
participants of the TwinsUK study for whom both SOMAscan and N-glycan data was available. In total,
1116 protein and 113 glycan traits overlapped between both studies and were further analysed (Tables
S1 and S2). We used inverse-normal scaled glycan and protein levels and linear models to determine
the correlation between both phenotypes in the QMDiab cohort and found 834 protein–glycan pairs
that associated with each other at a conservative Bonferroni level of significance (p < 3.96 × 10−7
= 0.05/1116/113). We attempted replication in the TwinsUK cohort; 145 out of the 834 Bonferroni
significant associations from the discovery study were nominally significant (p < 0.05) and displayed a
consistent trend in the TwinsUK study. These associations covered 62 glycan traits and 43 proteins.
Only two associations with a nominal p-value (p < 0.05) in TwinsUK showed a conflicting trend (Table
S3). We further arranged the replicated 145 associations into a matrix of 62 glycan by 43 protein with
the respective correlation r2 values and direction of association as entries (Figure 1, Tables S4 and S5).
Filtering of this matrix by protein or glycan trait(s) revealed specific protein glycosylation patterns of
which we summarize the most salient features next (Table 1 and Figure 2).
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Figure 1. Replicated protein–glycan associations. (a) Correlation (r2) between 62 glycan (rows) and 43 
protein traits (columns); positive associations are in blue, negative in red; darker values indicate 
stronger associations; (b) limited to proteins and glycans that have at least one association with r2 > 
0.4. A fully annotated and filterable matrix for all associations is available in Excel format as Tables 
S4 and S5. 
Figure 1. Replicated protein–glycan associations. (a) Correlation (r2) between 62 glycan (rows) and
43 protein traits (columns); positive associations are in blue, negative in red; darker values indicate
stronger associations; (b) li ited to proteins and glycans that have at least one association with r2 > 0.4.
A fully annotated and filterable matrix for all associations is available in Excel format as Tables S4
and S5.
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Figure 2. Scatterplots of selected protein–glycan associations. QMDiab (black circles), TwinsUK (red
dots); (a) IgG with percentage of M9 in total neutral plasma glycans, (b) IgM with FA2BG2 glycans, (c)
FUT5 with A3G3S(3,3,3)3 glycans, and (d) FCGR3B with A2(6)BG1 glycans.
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Table 1. Selected protein–glycan associations. Pearson correlations between inverse-normal scaled
traits and corresponding p-values are listed.
Protein Glycan Trait R QMDiab R TwinsUK p-ValueQMDiab
p-Value
TwinsUK
IgG PGP69: M9 in total neutralplasma glycans (GPn) −0.69 −0.36 8.0 × 10−50 1.5 × 10−2
IgG PGP93: core fucosylatedstructures 0.68 0.31 3.7 × 10−47 3.7 × 10−2
IgG PGP65: A2G2 in total neutralplasma glycans (GPn) −0.51 −0.35 3.8 × 10−24 1.6 × 10−2
IgG
PGP75: fucosylation of
digalactosylated structures in
total neutral plasma glycans
0.44 0.35 1.3 × 10−17 1.9 × 10−2
IgG PGP14: A2G2S(6)1 + A2G2S(3)1 −0.44 −0.30 1.4 × 10−17 4.3 × 10−2
IgM PGP16: FA2BG2S(3)1 +FA2BG2S(6)1 0.59 0.61 3.6 × 10−34 6.0 × 10−6
IgM
PGP44: monosialylation of
core-fucosylated
digalactosylated structures with
bisecting GlcNAc
0.51 0.48 2.5 × 10−24 8.0 × 10−4
IgM PGP11: FA2BG2 0.48 0.32 1.3 × 10−21 2.9 × 10−2
IgM
PGP42: monosialylation of
core-fucosylated
digalactosylated structures
without bisecting GlcNAc
0.46 0.41 4.6 × 10−19 4.1 × 10−3
IgM
PGP48: ratio of fucosylated
monosialylated and disialylated
structures (with bisecting
GlcNAc)
0.45 0.38 1.7 × 10−18 8.3 × 10−3
IgM
PGP54: ratio of fucosylated
monosialylated structures with
and without bisecting GlcNAc
0.40 0.56 1.1 × 10−14 4.4 × 10−5
IgM
PGP55: the incidence of
bisecting GlcNAc in all
fucosylated monosialylated
structures
0.40 0.56 1.1 × 10−14 4.4 × 10−5
SERPIND1 PGP97: trisialylated structures 0.53 0.29 8.0 × 10−27 4.9 × 10−2
SERPIND1 PGP102: trigalactosylatedstructures 0.53 0.35 8.7 × 10−26 1.7 × 10−2
SERPIND1 PGP105: triantennary structures 0.52 0.34 7.0 × 10−25 2.0 × 10−2
FUT5 PGP24: A3G3S(3,3,3)3 0.53 0.39 3.6 × 10−26 7.9 × 10−3
FUT5 PGP30: A4G4S(3,3,3)3 0.51 0.50 3.8 × 10−24 3.8 × 10−4
FUT5
PGP32: A4F1G3S(3,3,3)3 +
A4F1G3S(3,3,6)3 +
A4F1G3S(3,6,6)3
0.51 0.43 4.4 × 10−24 3.1 × 10−3
FUT5 PGP106: tetraantennarystructures 0.48 0.46 1.9 × 10−21 1.4 × 10−3
FUT5
PGP110: ratio of trisialylated
and tetrasialylated
tetragalactosylated structures
0.47 0.48 9.4 × 10−21 8.3 × 10−4
FUT5 PGP103: tetragalactosylatedstructures 0.47 0.45 2.4 × 10−20 1.5 × 10−3
FUT5 PGP36: A4F1G4S(3,3,3,6)4 0.45 0.30 6.3 × 10−19 4.0 × 10−2
FUT5 PGP92: antennary fucosylatedstructures 0.40 0.37 6.6 × 10−15 1.1 × 10−2
CD5L PGP16: FA2BG2S(3)1 +FA2BG2S(6)1 0.51 0.40 6.3 × 10−24 5.7 × 10−3
CD5L PGP108: glycan structures withbisecting GlcNAc 0.40 0.41 6.7 × 10−15 4.9 × 10−3
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Table 1. Cont.
Protein Glycan Trait R QMDiab R TwinsUK p-ValueQMDiab
p-Value
TwinsUK
CRP PGP97: trisialylated structures 0.45 0.38 3.3 × 10−18 8.8 × 10−3
CRP PGP29: A3F1G3S(3,3,3)3 +A3F1G3S(3,3,6)3 0.44 0.39 7.1 × 10−18 7.1 × 10−3
F9 (IX) PGP29: A3F1G3S(3,3,3)3 +A3F1G3S(3,3,6)3 0.44 0.38 6.9 × 10−18 9.7 × 10−3
F9 (IXab) PGP29: A3F1G3S(3,3,3)3 +A3F1G3S(3,3,6)3 0.44 0.38 7.1 × 10−18 9.3 × 10−3
F9 (IX) PGP92: antennary fucosylatedstructures 0.41 0.31 4.5 × 10−15 3.5 × 10−2
FCGR3B PGP3: A2(6)BG1 0.44 0.30 1.3 × 10−17 4.2 × 10−2
2.2. Immunoglobulin G
The strongest positive associations between immunoglobulin G (IgG, aptamer identifier: SL000467)
were with the percentage of core fucosylated N-glycan structures (FUC-C, glycan identifier: PGP93)
and with N-glycan structures containing bisecting GlcNAc in total plasma N-glycans (Btotal, PGP108),
and with the percentage of fucosylation of digalactosylated N-glycan structures in total neutral plasma
N-glycans (FG2n total /G2n, PGP75). This observation is in agreement with the well-established
fact that one of the most abundant IgG N-glycoforms is the fucosylated digalactosylated form and
that more than 90% of IgG N-glycans contain core fucose [26,27]. IgG N-glycans are predominantly
complex biantennary glycans and although glycoforms with bisecting GlcNAc make 5–10% of total
IgG N-glycans pool, it is known that bisecting suppresses further branching. Bisecting GlcNAc is
therefore limited to complex N-glycans with up to two antennas. The observed positive protein–glycan
associations in this case hence reflect the dominant N-glycan garments of the IgG proteins and the fact
that IgG is the major contributor of core fucosylated structures to the plasma N-glycome.
We also observed strong negative associations with IgG, i.e., with the percentage of mannose-rich
M9 (GP18n, PGP69) and with biantennary digalactosylated A2G2 (GP8n, PGP65) in neutral plasma
glycans, as well as with sialylated forms of biantennary digalactosylated A2G2S(6)1 + A2G2S(3)1
(PGP14) N-glycans in total plasma N-glycans. As N-glycans from IgG likely dominate the N-glycan
pool, these negative associations suggest that the relative contributions of other dominant N-glycans
decrease. For instance, Apo B-100 is probably the protein that most highly contributed with M9 to the
total plasma N-glycans pool [28,29]. We did not observe any complementary positive associations for
M9, likely because the relevant proteins were not targeted by the SOMAscan assay.
2.3. Immunoglobulin M
The strongest association of immunoglobulin M (IgM, SL000468) was with the percentage of
FA2BG2S(3)1 + FA2BG2S(6)1 in total plasma glycans (PGP16) and the percentage of FA2BG2 in
total plasma glycans (PGP11), followed by the percentage of mono-sialylation of core-fucosylated
digalactosylated structures without bisecting GlcNAc in total plasma N-glycans (PGP42). FA2BG2S1
glycans (S(3) and S(6) variants could not be separated under the chromatographic conditions used) are
dominant N-glycan structures on IgM and confirm previous knowledge. The positive association of
FA2BG2 with IgM was somewhat unexpected since it represents only around 4% of the IgM glycan
pool [30]. We also observed a positive association of IgM with N-glycan structures containing bisecting
GlcNAc in total plasma N-glycans (Btotal, PGP108), paralleling that of these glycans with IgG and also
with CD5 antigen-like (CD5L). The strongest association of CD5L was also with FA2BG2S1 glycans,
which is consistent with the observation that an IgM-associated peptide, later identified as CD5L, was
found in all IgM fractions purified from plasma or serum by various methods [31].
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2.4. Heparin Cofactor 2
The strongest associations for heparin cofactor 2 (SERPIND2, SL004466) were with the percentage
of trisialylated (PGP97), trigalactosylated (PGP102), and triantennary (PGP105) structures in total
plasma N-glycome, and specifically with the percentage of A3G3S(3,6)2 in total plasma N-glycans
(PGP22). Anticorrelations were with the percentage of agalactosylated structures in total plasma
N-glycans (PGP99) and with the percentage of antennary-fucosylation of tetragalactosylated structures
in total plasma N-glycans (PGP113). Not much is known about human SERPIND2 glycosylation, but
observations of diantennary and triantennary glycans on SERPIND2 in hamster ovary cells support
our findings [32].
2.5. Alpha-(1,3)-Fucosyltransferase 5
Levels of alpha-(1,3)-fucosyltransferase 5 (FUT5; SL014008) associated with the percentages of
A3G3S(3,3,3)3 (PGP24), A4G4S(3,3,3)3 (PGP30), A4F1G3S(3,3,3)3 + A4F1G3S(3,3,6)3 + A4F1G3S(3,6,6)3
(PGP32), and A4F1G4S(3,3,3,6)4 (PGP36) and consequently also with derived N-glycan traits, i.e.,
tetraanntenary structures (PGP106), the ratio of trisialylated and tetrasialylated tetragalactosylated
structures (PGP110), tetragalactosylated (PGP103), antennary fucosylated structures (Fuc-A, PGP92),
and antennary-fucosylation of trigalactosylated structures (PGP112). GP32 and GP36 contain antennary
fucose moieties and are hence expected to correlate with FUT5 activity. On the other hand, positive
associations of triantennary and tetraantennary sialylated N-glycans without antennary fucose are more
challenging to explain, since as potential substrates of FUT5 one would expect them to be negatively
correlated. However, much of the regulation of N-glycosylation remains enigmatic However, we still
do not know much about N-glycosylation regulation. It is possible that if the amount of substrate
increases, FUT5 abundance is upregulated as a response, but fucosylation activity itself is inhibited (for
example sterically). Furthermore, FUT5 itself is a glycoprotein but to the best of our knowledge no
detailed information about the type of glycans it carries is available. Interestingly, a recent GWAS with
N-glycans, identified SNP rs1169303 near HNF1A as associated with PGP30 [33]. HNF1A has been
shown to co-regulate the expression of most fucosyltransferases, including FUT5 [34]. Together, the
glycan associations with FUT5 hence likely reflect FUT5 activity.
2.6. C-Reactive Protein
The glycan associations involving C-reactive protein (CRP; SL000051) are driven by the
percentage of trisialylated structures (PGP97), and in particular by the specific trisialylated N-glycan
A3F1G3S(3,3,3)3 + A3F1G3S(3,3,6)3 (GP29). CRP is an important acute-phase protein and associated
with the future occurrence of coronary events [35]. As we have joint measurements of N-glycans and
CRP using clinical biochemistry methods available for 798 individuals in the TwinsUK study, we could
replicate these associations in a larger population sample (Table S6). In this case we used QMDiab
for replication. We found excellent agreement between both studies: of the 23 strongest CRP-glycan
associations observed in TwinsUK, only one was not significant (p < 3.96 × 10−7) in QMDiab, while only
four out of the 90 remaining weaker association were replicated in QMDiab. All replicated associations
had consistent effect sizes (Figure 3).
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2.7. ther Proteins
Lo affinity i unoglobulin ga a Fc region receptor III-B F 3B (SL008609) had a unique
association ith the percentage of 2(6)B 1 in total plas a -glycans ( P3). SL F7 (SL016928)
S fa ily e ber 7 sho e a positive association ith the percentage of F 2 2S(3,6)2
F 2B 2S(6,6)2 F 2B 2S(3,3)2 in total plasma N-glycans (GP21) and negative with the percentage of
A2G2S(3,6)2 + A2G2S(6,6)2 + A2G2S(3,3)2 in total plasma N-glycans (GP19).
3. Discussion
We report here what is to the best of our knowledge the first association study between the blood
circulating proteome and its corresponding N-glycome. We observed correlations between N-glycans
and proteins that confirm previous observations, and also found numerous novel associations that
require future experimental validation.
We are aware of the following caveats and limitations: As a population-based high-throughput
experiment, this study only provides a first step towards a better understanding of the interplay of
glycans and proteins. Targeted mass-spectrometry methods can for instance be deployed to confirm and
refine the protein-glycosylation patterns we report here. We chose not to correct for any confounding
factors that are known to influence protein glycosylation, such as age, sex, and diabetes. These
factors are creating the diversity that we probe by analysing protein–glycan correlations. Independent
studies with larger sample sizes are needed to further investigate their impact on specific protein
glycosylation patterns. The fact that the samples were collected from diverse populations increases
the variability in the data set and may have lessened the statistical power of the associations; the
uncovered correlations may thus be expected to be robust and generalizable across populations. The
size of the replication cohort was relatively small and did not allow for the application of a strict
Bonferroni level. However, by requiring Bonferroni significance in the discovery study, we believe that
we limited the number of false positives to a minimum, an assumption that is confirmed by the very
low level of discordant associations that reached nominal significance in the replication study, and by
the excellent agreement between QMDiab and TwinsUK for the CRP association, where we had larger
sample numbers available.
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4. Materials and Methods
4.1. Study Populations
The Qatar Metabolomics Study on Diabetes (QMDiab) is a cross-sectional diabetes case-control
study conducted between February and June 2012 at the Dermatology Department of HMC in Doha,
Qatar. QMDiab was approved by the Institutional Review Boards of HMC and Weill Cornell Medicine,
Qatar (WCM-Q) (research protocol #11131/11). Written informed consent was obtained from all
participants. The study enrolled 369 participants from mainly Arab, South Asian, and Filipino descent
who were between 23 and 71 years old [25]. The TwinsUK cohort is a registry of approximately
12,000 adult British twins, mostly female, recruited from the general population through national
media campaigns and representative of the UK population in terms of disease-related and lifestyle
characteristics [36]. All participants gave written, informed consent, and the Guy’s and St Thomas’
Hospital ethics committee approved the study. A total of 46 female subjects were characterised for
both total plasma N-glycans and proteomics data.
4.2. Sample Collection
In the QMDiab study, blood was drawn in the afternoon, after the general operating hours of the
morning clinic, into EDTA containers and processed using standardized protocols. Participants were
enrolled as they became available, in a random pattern with respect to age, gender, diabetes state, and
ethnicity. All procedures were conducted at the same location using identical protocols, instruments,
and study personnel. Lab personnel were blinded to all phenotype information. Samples were stored
on ice and processed within six hours after sample collection. Blood samples were centrifuged at
2500 g for 10 min, aliquoted, and then stored at −80 ◦C until analysis. For the TwinsUK study, blood
samples were taken after at least 6 h of overnight fasting. Serum and plasma EDTA samples were spun
at 3000 rpm for 10 min, aliquoted, and stored at −80 ◦C.
4.3. Proteomics Measurements
Proteins were measured using the SOMAscan assay as previously described [6,8]. This technique
is based on quantifying protein-specific aptamer binding using a DNA micro-array. Version 3 of
the SOMAscan assay convers 1129 distinct proteins. A total of 352 previously unthawed aliquots of
200 µL of EDTA plasma from QMDiab participants was analysed at the WCM-Q proteomics core
facility using this assay. The experiments were conducted following Somalogic Inc. protocols, using
Somalogic certified instrumentation, and under the direct supervision of experienced Somalogic
personnel. Primary data were sent to Somalogic for processing. This includes across-batch calibration
and several steps of quality control. No samples or individual probe data were excluded. TwinsUK
samples were analysed at the Somalogic laboratory (Boulder, CO, USA). Only proteins available for
both cohorts were analysed (N = 1116, Table S1).
4.4. Total Plasma N-Glycosylation Measurements
Unthawed aliquots of EDTA plasma from QMDiab and TwinsUK were analysed by Genos Ltd.
(Zagreb, Croatia) using ultra-performance liquid chromatography (UPLC) glycoprofiling. Glycans
were released from total plasma proteins and labelled as described previously [37]. Briefly, 10 µL of
plasma sample was denatured with the addition of 20 µL 2% (w/v) SDS (Invitrogen, Carlsbad, CA, USA)
and N-glycans were released with the addition of 1.2 U of PNGase F (Promega, Madison, WI, USA).
The released N-glycans were labelled with 2-aminobenzamide (Sigma-Aldrich, St. Louis, MO, USA).
Free label and reducing agent were removed from the samples using hydrophilic interaction liquid
chromatography solid-phase extraction. A 0.2 µm 96-well GHP filter-plate (Pall Corporation, USA) was
used as stationary phase. Samples were loaded into the wells and after a short incubation washed 5×
with cold 96% acetonitrile (ACN). Glycans were eluted with 2 × 90 µL of ultrapure water after 15 min
shaking at room temperature, and combined eluates were stored at −20 ◦C until use. Total plasma
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N-glycans were then analysed by hydrophilic interaction ultra-performance liquid chromatography
(HILIC-UPLC) as described previously [37]. Briefly, fluorescently labelled N-glycans were detected on
an Acquity UPLC instrument (Waters, USA) using excitation and emission wavelengths of 250 and
428 nm, respectively. Labelled N-glycans were separated on a Waters BEH Glycan chromatography
column, 150 × 2.1 mm i.d., 1.7 µm BEH particles, with 100 mM ammonium formate, pH 4.4, as solvent
A and ACN (Fluka, USA) as solvent B. The separation method used a linear gradient of 30–47% solvent
A at flow rate of 0.56 mL/min in a 23 min analytical run. Total plasma N-glycans were separated into
39 chromatographic peaks (Figure 4) and then further quantified and annotated into 36 primary and
77 derived glycan traits (Table S2) [33]. Abbreviations are as follows: all N-glycans have core sugar
sequence consisting of two N-acetylglucosamines (GlcNAc) and three mannose residues; F indicates
a core fucose α1–6 linked to the inner GlcNAc; Ax indicates the number of antennas (GlcNAc) on
trimannosyl core; Gx indicates the number of β1–4 linked galactoses on antenna; G1 indicates that the
galactose is on the antenna of the α1–6 mannose; Sx indicates the number (x) of sialic acids linked to
galactose. Structures in each peak were derived according to Saldova et al. [38].
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